Brian Stigall, MD
Sports Medicine · New Braunfels, TXNPI 1104834340
Payments from drug & device makers
Across 112 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$173
- Amgen$162
- Medtronic$131
- Johnson & Johnson$125
- Lilly USA, LLC$125
- Amarin Pharma, Inc.$122
- plus $863 from 16 others
What the payments were for
- Food & beverage$1,68899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $173 |
| Amgen | 10 | $162 |
| Medtronic | 1 | $131 |
| Johnson & Johnson | 9 | $125 |
| Lilly USA, LLC | 15 | $125 |
| Amarin Pharma, Inc. | 10 | $122 |
| Boehringer Ingelheim | 8 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $102 |
| GSK | 5 | $82 |
| AstraZeneca | 6 | $82 |
| Genentech USA, Inc. | 4 | $70 |
| Novartis | 4 | $69 |
| Antares Pharma, Inc. | 4 | $63 |
| Radius Health, Inc. | 4 | $60 |
| Novo Nordisk | 4 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Astellas Pharma US Inc | 3 | $36 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,700 in reported general payments places this provider in the 45th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $91,955 |
| TrulicityDulaglutide | 46 | $45,100 |
| JardianceEmpagliflozin | 28 | $33,259 |
| EliquisApixaban | 24 | $27,490 |
| ProliaDenosumab | 15 | $25,628 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $22,354 |
| JanuviaSitagliptin Phosphate | 28 | $19,990 |
| MounjaroTirzepatide | 17 | $17,252 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $14,987 |
| XareltoRivaroxaban | 16 | $14,807 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,893 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $9,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,644 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,595 |
| VascepaIcosapent Ethyl | 11 | $4,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $49 | $91,95598 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $125 | $62,35163 claims |
| Boehringer IngelheimJardiance | $106 | $33,25928 claims |
| AmgenProlia | $162 | $25,62815 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $82 | $18,01832 claims |
| Johnson & JohnsonXarelto | $125 | $14,80716 claims |
| AstraZenecaSymbicort | $82 | $3,47114 claims |
| AbbVieSynthroid | $173 | $3,31537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 437 sports medicine providers in Texas.
Other sports medicine in New Braunfels
- Timothy VachrisAustin$5.7M
- Thomas DeberardinoSan Antonio$3.5M
- Mark HutchensAustin$2.5M
- Robert ScheinbergDallas$2.2M
- Marc LabbeThe Woodlands$2M
- Walter LoweHouston$1.4M
- Reed BartzSunnyvale$1.2M
- David BrownHouston$920K
- James GregoryHouston$848K
- Matthew HiggsHouston$634K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.